David Taieb

David Taieb at Aix-Marseille University is a leading expert in nuclear medicine and systemic treatment of pheochromocytoma, contributing to the FIRSTMAPPP trial establishing sunitinib activity in malignant pheochromocytoma and paraganglioma. His research on SSTR expression and PRRT in paraganglioma, combined with MIBG imaging, has advanced the precision medicine approach to these rare tumors. He has co-authored European guidelines for pheochromocytoma and has contributed to understanding molecular imaging biomarkers that predict systemic therapy response. His work bridges nuclear medicine diagnostics and therapeutic nuclear medicine in pheochromocytoma.